Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Catalent Inc    CTLT

CATALENT INC (CTLT)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 01/17 10:51:14 am
34.755 USD   +0.36%
2017CATALENT INC : annual earnings release
2016CATALENT INC : annual earnings release
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Catalent : to double biomanufacturing capacity with $200m investment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:39am EST

Catalent will use the funds to enlarge drug substance manufacturing and drug product fill/finish capacity.

The $200m (173m) investment will take place at Catalents biologics manufacturing sites in Madison, Wisconsin, and Bloomington, Indiana. The decision follows the expansion of its biologics packaging capacity, at the latter site.

The improvement upon current capacity in drug substance manufacturing and fill/finish will take place over three years.

It will see mammalian cell culture capacity increased with two new suites, each housing a two 2,000 litre single-use bioreactor system. Fill/finish capacity will be increased by an expanded Bloomington site, which will grow by 79,000-sq-ft to accommodate a high-speed flexible vial line operating at 300 units per minute.

Brian Riley, VP of operations, biologics and specialty drug delivery at Catalent, told us that the expansion is required to meet increasing demand in the late-stage clinical and commercial supply phases.

The Bloomington facility recently achieved regulatory approval for a twentieth commercial product, so part of the expansion at both sites is necessary to fulfil increasing demand from existing customers programs, but the expansion is also in anticipation of new business too, Riley explained.

The upgrade to both facilities will also add new staff members over the coming years. Riley could not specify a precise number but said, we anticipate adding over 100 new roles in Madison, and up to 200 new jobs in Bloomington by the end of 2024.

Catalent acquired the Bloomington facility as part of its $950m takeover of Cook Pharmica in 2017. Subsequently, the company revealed that it would be looking to the site, with it operating at 45% of its capacity upon acquisition.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CATALENT INC
09:19aCATALENT : Assay Automation to be Presented at WCBP Symposium
PU
01/16CATALENT : Invests $200 Million in Wisconsin and Indiana Sites
AQ
01/12CATALENT : Invests $200M in Fast-Growing Biologics Manufacturing Business
AQ
01/12CATALENT : to double biomanufacturing capacity with $200m investment
AQ
01/10CATALENT : commences $200M investment in Wisconsin, Indiana manufacturing plants
AQ
01/09CATALENT : $100M expansion of pharmaceutical operations set for Indiana
AQ
01/08CATALENT : to expand Wisconsin biomanufacturing operation
AQ
01/07CATALENT : Invests $200 Million to Expand Biologics Capacity and Capabilities
BU
2018CATALENT, INC. : to Present at the 37th Annual J.P. Morgan Health Care Conferenc..
BU
2018CATALENT : Celebrates 20 Years at Philadelphia Facility
PU
More news
Financials ($)
Sales 2019 2 510 M
EBIT 2019 388 M
Net income 2019 148 M
Debt 2019 1 729 M
Yield 2019 -
P/E ratio 2019 36,29
P/E ratio 2020 25,49
EV / Sales 2019 2,69x
EV / Sales 2020 2,48x
Capitalization 5 034 M
Chart CATALENT INC
Duration : Period :
Catalent Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 43,9 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
John R. Chiminski Chairman, President & Chief Executive Officer
Alessandro Maselli Senior Vice President-Global Operations
Wetteny Joseph CFO, Principal Accounting Officer & Senior VP
Jack L. Stahl Lead Independent Director
Rolf Allan Classon Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALENT INC11.06%5 034
JOHNSON & JOHNSON0.24%343 400
PFIZER-2.11%244 238
NOVARTIS3.97%225 626
ROCHE HOLDING LTD.5.61%223 510
MERCK AND COMPANY-2.36%194 014